Phase 2, Phase 3 Recruiting NIH
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Maryland: - Site 153 — Columbia, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Maryland: - University of Marlyand Baltimore — Baltimore, Maryland
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Maryland: - GSK Investigational Site — Columbia, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…
Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Maryland: - University of Maryland School of Medicine — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…
Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Maryland: - Research Site — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objecti…
Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT ID: NCT04915183
Sites in Maryland: - University of Maryland Medical Center — Baltimore, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds…
Sponsor: University of Maryland, Baltimore
NCT ID: NCT06088381
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
- Upper Chesapeake Health — Bel Air, Maryland
- Central Maryland Radiation Oncology — Columbia, Maryland
- Baltimore Washington Medical Center — Glen Burnie, Maryland
Phase 2 Recruiting Academic/Other
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…
Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this stu…
Sponsor: Precision Biologics, Inc
NCT ID: NCT03476681
Sites in Maryland: - National Cancer Institute — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with certain types of HNSCC survive for 5 years. Objective: To test a new drug treatme…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161545
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
The NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible for curative…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07209189
Sites in Maryland: - Johns Hopkins Hospital East Baltimore — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can be…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT04927416
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Maryland: - Exelixis Clinical Site #14 — Baltimore, Maryland
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Maryland: - United Theranostics — Glen Burnie, Maryland
Phase 1 Recruiting NIH
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
Phase 1 Recruiting Industry
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT05635643
Sites in Maryland: - University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Phase 1 Recruiting Academic/Other
The goal of this study is to evaluate combined radioactive iodine (RAI, 131-I) and external beam radiotherapy (XRT) to optimize the radiation dose delivered to treat well differentiated thyroid cancers (DTC) with iodine-avid metastases. Th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04892303
Sites in Maryland: - The Johns Hopkins SKCCC — Baltimore, Maryland
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Maryland: - Mercy Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
- MedStar Southern Maryland Hospital Center — Clinton, Maryland
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Maryland: - Christiana Care - Union Hospital — Elkton, Maryland